



Sub C
B1
Degradation (RID) complex having a RID α polypeptide and a RID β polypeptide, wherein the RID complex is expressed in the cell in an amount sufficient to inhibit apoptosis of the cell, and wherein the cell expresses Fas, TNFR-1, DR3, TRAIL-R1, or TRAIL-R2.

B2
3. (Amended) The method of claim [2]1 wherein the polynucleotide comprises a recombinant adenovirus vector.

6. (Amended) The method of claim [5]3 wherein the cell is a leukocyte.

Sub C3
B3
7. (Amended) The method of claim [5]3 wherein the cell is a cell in a[comprises a] transplant tissue.

Sub C4
B4
10. (Twice amended) A method for decreasing apoptosis of target cells in a patient comprising treating the target cells of the patient with [an effective amount of]a recombinant polynucleotide encoding a Receptor Internalization and Degradation (RID) complex having a RID α polypeptide and a RID β polypeptide, wherein the RID complex is expressed in the cell in an amount sufficient to inhibit apoptosis of the cell, and wherein the target cells expresses Fas, TNFR-1, DR3, TRAIL-R1, or TRAIL-R2.

B5
12. (Amended) The method of claim [11]10 wherein the polynucleotide comprises a recombinant adenovirus vector.

B6
17. (Twice amended) A method for decreasing leukocyte apoptosis in a patient comprising:
(1) withdrawing leukocytes from the patient,
(2) treating the leukocytes with [an effective amount of]a recombinant polynucleotide encoding a RID complex having a RID α polypeptide and a RID β polypeptide, wherein the RID complex is expressed in the cell in an amount sufficient to inhibit apoptosis of the cell, and
(3) administering the treated leukocytes to the patient.

B7
19. (Amended) The method of claim [18]17 wherein the recombinant polynucleotide comprises a recombinant adenovirus vector.

BEST AVAILABLE COPY